Health
Report: Consumer Views on Ozempic, Other Weight Loss Drugs
Report summary
GLP-1 drugs like Ozempic, Wegovy and Mounjaro have been hailed as a game-changing weight loss solution, and for good reason. Celebrities and influencers are touting their benefits, prescriptions are soaring, the drugmakers behind them are generating massive profits, and new markets are being explored.
The early success of these drugs is translating to sustained interest from consumers, but concerns abound, especially related to high prices and potential long-term side effects.
Still, use of weight loss drugs looks poised to further grow, and the impacts could be felt by many companies outside of the health industry. Food & beverage brands that tailor offerings, like smaller portion sizes and healthier choices, will be well suited to serve a more health-conscious consumer today and in the future.
This report compiles analysis from our previous research and builds upon it to uncover what’s driving persistent interest in Ozempic, and drugs like it, and what brands should do about it.
Key Takeaways
- A majority of Americans feel they need to lose weight: More than half of U.S. adults say they feel they need to lose weight — and not just a few pounds.
- Interest in weight loss drugs has been persistent: Millennials, high earners and those who have heard a lot about the drugs are driving interest.
- Consumers see many positive benefits: Improving self-image and physical health are just a few of the positive impacts of weight loss drugs, according to consumers.
- But cost remains a huge barrier: The potential for long-term side effects is also worrisome to consumers and those interested in the medications.
- Traditional dieting methods are seen as more effective: Consumers don’t necessarily think weight loss drugs are ineffective, but many have yet to make up their minds about them.
Data Downloads
Morning Consult Pro+ subscribers are able to access the data sets that power our reports and analysis. Learn more and get access.
Methodology
Morning Consult Research Intelligence data featured in this report draws from surveys conducted April 28-30, Aug. 3-5 and Oct. 16-19, 2023, among roughly 2,200 U.S. adults each.
All survey interviews were conducted online, and the data was weighted to approximate populations of adults based on age, gender, race, educational attainment, region, gender by age and race by educational attainment. Top-line results from the surveys have a margin of error of +/-2 percentage points.
Be sure to catch up on all our previous weight loss drug research below.
About the authors
Nicki Zink is deputy head of Industry Analysis. Her team identifies trends affecting key demographics across food & beverage, travel & hospitality and financial services. Prior to joining Morning Consult, Nicki served as the head of digital intelligence at Purple Strategies, a corporate reputation and strategy firm. She graduated from Miami University with a bachelor’s degree in mass communication. For speaking opportunities and booking requests, please email [email protected].
Brian Yermal previously worked at Morning Consult as a research editor on the Industry Intelligence team.
